Anixa Biosciences (ANIX) Peer Comparison
$3.60
$-0.01
(-0.14%)
As on 27-Aug-2026 16:24EDT
Market cap
$126 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
8.7
Div. Yield
0 %
Edit
| Anixa Biosciences (ANIX) | Champions Oncology (CSBR) | Biovie Inc (BIVI) | Alzamend Neuro Inc (ALZN) | Bio-Techne Corp (TECH) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
126 | 69 | 16 | 7 | 11,268 |
Revenue ($ Mln) |
-- | 59 | -- | -- | 1,215 |
Net Profit ($ Mln) |
-10.07 | -1.18 | -22.07 | -8.77 | 181.86 |
Net Margin (%) |
-- | -1.98 | -- | -- | 14.97 |
RoE (%) |
-67.38 | -30.48 | 0.00 | -373.18 | 9.03 |
Price to Earnings |
-- | -- | -- | -- | 62.34 |
Price-To-Book |
8.72 | 18.09 | 1.53 | 10.65 | 5.34 |
Income Statement ($ Mln)
| Anixa Biosciences (ANIX) | Champions Oncology (CSBR) | Biovie Inc (BIVI) | Alzamend Neuro Inc (ALZN) | Bio-Techne Corp (TECH) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
0.00 | 56.94 | 0.00 | 0.00 | 1,215.04 |
|
Cost of Revenue
|
0.04 | 28.39 | 0.18 | 0.05 | 415.97 |
|
Gross Profit
|
-0.04 | 28.56 | -0.23 | -0.05 | 790.27 |
|
Operating Expenses
|
11.67 | 23.71 | 22.48 | 4.50 | 547.18 |
|
Operating Profit (EBIT)
|
-11.70 | 4.85 | -22.65 | -4.50 | 251.89 |
|
Other Income
|
-- | -- | 0.00 | -- | 0.00 |
|
Profit before Tax
|
-11.03 | 4.63 | -22.07 | -4.51 | 240.68 |
|
Provision for Tax
|
0.14 | -0.08 | 0.00 | -- | 58.82 |
|
Profit after Tax (Net Income)
|
-10.93 | 4.70 | -22.07 | -4.51 | 181.86 |
|
Minority Interest
|
-- | -- | 0.00 | -- | 0.00 |
|
Consolidated Profit
|
-- | -- | 0.00 | -- | 0.00 |
Liabilities ($ Mln)
| Anixa Biosciences (ANIX) | Champions Oncology (CSBR) | Biovie Inc (BIVI) | Alzamend Neuro Inc (ALZN) | Bio-Techne Corp (TECH) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
15.16 | 3.77 | 10.27 | 3.97 | 2,108.22 |
|
Minority Interest
|
-- | -- | 0.00 | -- | 0.00 |
|
Non-Current Liabilities
|
0.16 | 4.72 | 0.18 | 0.00 | 314.81 |
|
Current Liabilities
|
1.97 | 23.85 | 3.80 | 0.63 | 163.70 |
|
Total Liabilities
|
16.08 | 32.34 | 21.56 | 4.60 | 2,557.87 |
Assets ($ Mln)
| Anixa Biosciences (ANIX) | Champions Oncology (CSBR) | Biovie Inc (BIVI) | Alzamend Neuro Inc (ALZN) | Bio-Techne Corp (TECH) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
0.19 | 9.98 | 0.61 | 0.43 | 1,842.33 |
|
Current Assets
|
15.89 | 22.37 | 13.64 | 4.18 | 744.40 |
|
Total Assets
|
16.08 | 32.34 | 21.56 | 4.60 | 2,557.87 |
|
Total Debt*
|
0.20 | 6.11 | 0.28 | 0.30 | 274.15 |
|
Net Current Assets
|
13.92 | -1.48 | 0.00 | 3.54 | 0.00 |
Cashflow ($ Mln)
| Anixa Biosciences (ANIX) | Champions Oncology (CSBR) | Biovie Inc (BIVI) | Alzamend Neuro Inc (ALZN) | Bio-Techne Corp (TECH) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-7.17 | 7.39 | -19.03 | -6.57 | 287.56 |
|
Cash Flow from Investing Activities
|
4.87 | -0.39 | -- | -0.30 | -35.18 |
|
Cash from Financing Activities
|
2.28 | 0.17 | 12.73 | 10.44 | -253.91 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Anixa Biosciences (ANIX) | Champions Oncology (CSBR) | Biovie Inc (BIVI) | Alzamend Neuro Inc (ALZN) | Bio-Techne Corp (TECH) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-61.40 | 61.04 | -85.61 | -539.17 | 3.03 |
|
ROE (%)
|
-62.16 | 503.05 | -149.47 | -657.17 | 8.83 |
|
ROA (%)
|
-58.01 | 16.08 | -85.34 | -172.50 | 6.00 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | 20.25 |
|
Net Margin (%)
|
-- | 8.26 | -- | -- | 14.97 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | 0.00 |
Growth Ratios
| Anixa Biosciences (ANIX) | Champions Oncology (CSBR) | Biovie Inc (BIVI) | Alzamend Neuro Inc (ALZN) | Bio-Techne Corp (TECH) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-1.00 | 0.14 | -- | -- | -0.38 |
|
EBIT Growth (%)
|
-- | -- | -28.86 | -- | 130.05 |
|
Net Profit Growth (%)
|
12.96 | 164.61 | -25.83 | 54.61 | 147.77 |
|
EPS Growth (%)
|
-- | -- | 75.00 | -- | 155.17 |
|
Book Value Growth (%)
|
-- | -- | 5.81 | -- | 9.00 |
Valuation Ratios
| Anixa Biosciences (ANIX) | Champions Oncology (CSBR) | Biovie Inc (BIVI) | Alzamend Neuro Inc (ALZN) | Bio-Techne Corp (TECH) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-- | -- | -0.78 | -- | 109.18 |
|
Price / Book Value
|
-- | -- | 0.72 | -- | 4.18 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
1.36 | -0.59 | 0.21 | 0.89 | 38.25 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Anixa Biosciences (ANIX) | Champions Oncology (CSBR) | Biovie Inc (BIVI) | Alzamend Neuro Inc (ALZN) | Bio-Techne Corp (TECH) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.01 | 1.62 | 0.00 | -0.12 | 0.00 |
|
Short term debt to equity ratio
|
0.00 | 0.39 | 0.01 | -0.12 | 0.00 |
|
Current Ratio
|
8.08 | 0.94 | 3.59 | 6.58 | 4.55 |
|
Quick Ratio
|
-- | 0.63 | 3.59 | -- | 3.35 |
|
Interest Coverage
|
-- | 171.33 | -1,232.05 | -249.42 | 45.53 |
Operating Efficiency Ratios
| Anixa Biosciences (ANIX) | Champions Oncology (CSBR) | Biovie Inc (BIVI) | Alzamend Neuro Inc (ALZN) | Bio-Techne Corp (TECH) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
-- | 19.73 | -- | -- | 17.83 |
|
Asset Turnover
|
0.00 | 1.95 | 0.00 | 0.00 | 0.40 |
|
Receivable days
|
-- | 66.58 | -- | -- | 67.12 |
|
Inventory Days
|
-- | 0.00 | -- | -- | 157.03 |
|
Payable days
|
3,500.31 | 64.64 | 4,607.67 | 12,812.62 | 26.92 |
|
Cash Conversion Cycle
|
-- | 1.94 | -- | -- | 197.23 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
